Detalhe da pesquisa
1.
Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study.
J Neurol Neurosurg Psychiatry
; 2022 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35649699
2.
The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis.
Eur Radiol
; 32(5): 3576-3587, 2022 May.
Artigo
Inglês
| MEDLINE | ID: mdl-34978580
3.
A man in his twenties with dizziness, double vision and peripheral facial palsy. / Mann i 20-årene med svimmelhet, dobbeltsyn og perifer facialisparese.
Tidsskr Nor Laegeforen
; 138(15)2018 10 02.
Artigo
Inglês, Norueguês
| MEDLINE | ID: mdl-30277051
4.
Interferon ß1a treatment does not influence serum Epstein-Barr virus antibodies in patients with multiple sclerosis.
Mult Scler Relat Disord
; 70: 104530, 2023 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-36701908
5.
Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis: A Systematic Review.
Neurology
; 98(15): e1562-e1573, 2022 04 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35173016
6.
The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
; 9(5)2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35738901
7.
Treatment non-adherence as a trigger for status epilepticus: An observational, retrospective study based on therapeutic drug monitoring.
Epilepsy Res
; 113: 28-33, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-25986189